EQUILLIUM, INC. Current Federal Tax Expense (Benefit)
EQUILLIUM, INC. (EQ) reported Current Federal Tax Expense (Benefit) of $340.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-25
- EQUILLIUM, INC. current federal tax expense (benefit) for fiscal 2024 was $340.00K, a 39.72% decline from fiscal 2023.
- EQUILLIUM, INC. current federal tax expense (benefit) for fiscal 2023 was $564.00K.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $340.00K 10-K · filed 2026-03-25 |
| 2023-12-31 | $564.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |